Group 1 - The company held its 19th meeting of the 10th Board of Directors on December 4, 2025, via communication, with all 13 directors present, complying with relevant laws and regulations [2][4]. - The Board approved multiple proposals regarding the revision of the company's articles of association and governance systems, which will be submitted to the shareholders' meeting for further approval [3][5][6]. Group 2 - The company announced the convening of the 2025 Fourth Extraordinary General Meeting of Shareholders on December 22, 2025, in Shanghai, with specific voting procedures outlined [29][85]. - The meeting will include proposals that require a special resolution, needing more than two-thirds of the valid voting rights held by attending shareholders to pass [90].
派斯双林生物制药股份有限公司第十届董事会第十九次会议(临时会议)决议公告